- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04087681
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1) (EXPECT-1)
Pilot Study to Assess Success Factors and Barriers for Preparation of a Phase 3 Study With ExPEC10V in Adults Aged 60 Years or Older and in Stable Health
Study Overview
Status
Conditions
Detailed Description
Invasive ExPEC disease (IED) is defined as an acute illness consistent with bacterial infection that is microbiologically confirmed by the isolation and identification of E. coli from blood or other normally sterile body sites, or by the isolation and identification of E. coli from urine in a patient with signs and symptoms of invasive disease and no other identifiable source of infection. Adults aged 60 years or older have an increased risk of developing IED. To date, there is no vaccine available to prevent IED. ExPEC10V is a 10 valent vaccine candidate in development by Janssen R&D for the prevention of IED in adults aged 60 years and older. A Phase 3 clinical study is planned to investigate the efficacy and safety of this vaccine. To obtain insight in the feasibility and design of the Phase 3 study, a pilot study is required.
This pilot study is a prospective, multicenter, observational study conducted in a maximum of eight countries in Europe, North-America and Asia. Participant recruitment will be done in primary care. In each participating country a local primary care network encompassing approximately 40,000 persons and a local hospital, where patients are referred to in case of a suspicion of IED, will participate in this study.
Database screening at the primary care centers will be performed to identify and invite potential eligible study participants. Upon consent, each study participant will be followed for a period of maximum 12 months after enrollment in the study. At baseline, demographic data and medical history data will be collected. During the follow-up period, any referral of study participants to a hospital for any reason including IED will be collected. IED identification and Medical Resource Utilization (MRU) during the follow-up period will be performed by regular telephone calls with all study participants. At the end of the study, the primary care files will also be checked for MRU. If a participant is diagnosed with IED and admitted to the hospital, the following data will be collected: medical history and treatment received 90 days prior to the IED, clinical and laboratory data, data on the treatment and outcome of IED and data on MRU related to IED. Data will be collected on Day 1 of IED diagnosis (signs/ symptoms) and Day 28 after IED diagnosis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Greater Sudbury, Canada
- Duke Clinical Research Institute
-
-
-
-
-
Limoges, France, 87042
- Chu Limoges - Cic
-
-
-
-
-
Köln, Germany, 50937
- UKK Uniclinic Cologne
-
-
-
-
-
Verona, Italy, 37129
- University of Verona
-
-
-
-
Chiyoda-ku
-
Tokyo, Chiyoda-ku, Japan, - 5-2 Nishikanda, 3-chome
- Janssen Pharmaceutical K.K.
-
-
-
-
-
Seville, Spain, 41013
- - Andalusian Public Foundation for Health Research Management in Seville (FISEVI)
-
-
-
-
-
Oxford, United Kingdom, OX1 2JD
- University of Oxford
-
-
-
-
North Carolina
-
Durham, North Carolina, United States, 27701
- Duke Clinical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participant is willing to provide written informed consent prior to inclusion.
- Participant is male or female preferably with a history of UTI in the previous 10 years. Participant without a (known) history of UTI in the previous ten years may also be enrolled.
- Participant is aged 60 years or older on the day of signing the informed consent form (ICF).
- Participant is willing to be available for contact with investigator for the duration of the study.
- Participant is ambulatory and lives in the community or in assisted-living or long-term care residential facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
- Based on the clinical judgment of the investigator, participant must be in stable health. Participants may have underlying illnesses such as hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), type 2 diabetes mellitus, as long as their signs and symptoms are stable and medically controlled.
Exclusion Criteria:
- Participant has a serious chronic disorder, including severe COPD or clinically significant CHF, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g. compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments.
- Participant has history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence).
- Participant has had major psychiatric illness and/or drug or alcohol abuse which in investigators opinion would compromise the participant's safety and/or compliance with the study procedures.
- Participant who, in the opinion of the investigator, is unlikely to adhere to the requirements of the study, or is unlikely to complete the full course of the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Elderly 60+ preferably those with increased risk of IED
Study participants are aged 60 years or older in stable health, preferably with a history of urinary tract infection in the previous 10 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant enrolment rate (% of patients screened/invited vs. enrolled)
Time Frame: 3 months
|
Participant enrolment rate (% of patients screened/invited vs. enrolled)
|
3 months
|
Number of hospital admissions of participants reported by the hospital versus the number of hospital admissions obtained through medical record checks by the primary care center versus the number of hospital admissions reported by participants narrative
Time Frame: 12 months
|
Number of hospital admissions of participants reported by the hospital versus the number of hospital admissions obtained through medical record checks by the primary care center versus the number of hospital admissions reported by participants narrative
|
12 months
|
Number of IED hospital admissions of participants reported by the hospital vs. the number of IED hospital admissions obtained by medical record checks of the primary care center vs. the number of IED hospital admissions reported by participants narrative
Time Frame: 12 months
|
Number of IED hospital admissions of participants reported by the hospital vs. the number of IED hospital admissions obtained by medical record checks of the primary care center vs. the number of IED hospital admissions reported by participants narrative
|
12 months
|
Description of medical assessment pathways based on participants medical files.
Time Frame: 12 months
|
Description of medical assessment pathways based on participants medical
|
12 months
|
Description of standard of care diagnostic methods based on participants medical files.
Time Frame: 12 months
|
Description of standard of care diagnostic methods based on participants medical files.
|
12 months
|
Description of treatment of bacteremic and nonbacteremic IED based on participants medical files.
Time Frame: 12 months
|
Description of treatment of bacteremic and nonbacteremic IED based on participants medical files.
|
12 months
|
Incidence of IED (number % of IED cases in the group of study participants)
Time Frame: 12 months
|
Incidence of IED (number % of IED cases in the group of study participants)
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Miquel Ekkelenkamp, Dr., UMC Utrecht
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAC52416BAC0005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on E.Coli Infections
-
UMC UtrechtJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE. Coli InfectionUnited States, Italy, United Kingdom, Canada, France, Germany, Japan, Spain
-
London School of Hygiene and Tropical MedicineIndian Institute of Technology KanpurCompletedDiarrhea | E.Coli Infections
-
SNIPR Biome Aps.Wellcome Trust; Biomedical Advanced Research and Development AuthorityCompletedBloodstream Infection | E.Coli InfectionsUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedAcute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.ColiFrance
-
Therapeutic Advances in Childhood Leukemia ConsortiumTerminatedRelapsed Acute Lymphoblastic Leukemia | Allergy to PEG e.Coli Asparaginase | Allergy to Native e.Coli AsparaginaseUnited States
-
University of TartuEstonian University of Life SciencesUnknownMethicillin Resistant Staphylococcus Aureus (MRSA) | Vancomycin (Glycopeptide) Resistant Enterococcus (VRE) | ESBL Producing E.Coli | ESBL Producing K.Pneumoniae | Multidrug Resistant P.Aeruginosa | Carbapenem Resistant P.Aeruginosa
-
SEAMEO Regional Centre for Food and NutritionLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruitingProtozoan Infections | Birth Weight | Weight Gain | Vitamin A Deficiency | Folate Deficiency | Zinc Deficiency | Child Development | Salmonella Infections | Anemia, Iron Deficiency | Fatty Acid Deficiency | Birth Length | B12 Deficiency Vitamin | Mineral Deficiency | E. Coli Infection | Shigella Infection | Amino Acid Deficiency and other conditionsIndonesia
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
GlaxoSmithKlineCompleted